Christopher M Frampton
Overview
Explore the profile of Christopher M Frampton including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
127
Citations
3036
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Douglas K, Odering Z, Jordan J, Crowe M, Lacey C, Frampton C, et al.
Bipolar Disord
. 2025 Mar;
PMID: 40026199
Introduction: Inpatient depression is associated with high morbidity and significant cognitive impairment. Inpatient treatment often focuses on short-term stabilization with medication. Readmission rates are high. We examined the impact of...
2.
Kew B, Doogue M, McNeill R, Zhang M, Rucklidge J, Frampton C, et al.
Br J Clin Pharmacol
. 2025 Feb;
PMID: 39993734
Aims: Daily broad-spectrum micronutrients are being used by the general public and formulations are receiving research interest in mental health settings. Despite concerns about combining medicines and broad-spectrum micronutrients in...
3.
Woods C, McIntosh V, Frampton C, Carter F, Colhoun H, Jordan J, et al.
BJPsych Open
. 2024 Dec;
11(1):e13.
PMID: 39727239
Background: History of prior mental disorder, particularly post-traumatic stress disorder (PTSD), increases risk for PTSD following subsequent trauma exposure. However, limited research has examined differences associated with specific prior mental...
4.
Scott N, Charles C, Prickett T, Frampton C, Richards A, Rademaker M
J Am Heart Assoc
. 2024 Nov;
13(23):e036689.
PMID: 39575752
Background: LCZ696 (sacubitril/valsartan) antagonizes the renin-angiotensin system while simultaneously augmenting the natriuretic peptides (NPs). Inhibition of phosphodiesterase 9 inhibition (PDE9i), which hydrolyses NP-generated cGMP may be a more specific means...
5.
Lynskey S, Frampton C, Lynskey T
N Z Med J
. 2024 Jan;
137(1588):15-24.
PMID: 38261771
Aim: This single surgeon case series with up to 29-year follow-up evaluated the survival of the Oxford unicompartmental knee replacement (UKR) for isolated medial compartment osteoarthritis. Method: Four hundred and...
6.
Butler J, Frampton C, Moore G, Barclay M, Jardine D
Clin Auton Res
. 2023 Aug;
33(6):623-633.
PMID: 37598402
Purposes: Habitual coffee drinking is ubiquitous and generally considered to be safe despite its transient hypertensive effect. Our purpose was to determine the role of the sympathetic nervous system in...
7.
Tay M, Monk A, Frampton C, Hooper G, Young S
Bone Joint J
. 2023 Feb;
105-B(3):269-276.
PMID: 36854342
Unicompartmental knee arthroplasty (UKA) has higher revision rates than total knee arthroplasty (TKA). As revision of UKA may be less technically demanding than revision TKA, UKA patients with poor functional...
8.
Scott N, Prickett T, Charles C, Frampton C, Richards A, Rademaker M
JACC Heart Fail
. 2023 Feb;
11(2):227-239.
PMID: 36752488
Background: The natriuretic peptides (NPs) are potent natriuretic/diuretic and vasodilatory factors, and augmentation of their levels or signaling via inhibition of the enzymes neprilysin (NEP) and phosphodiesterase 9 (PDE9), respectively,...
9.
Tay M, Young S, Frampton C, Hooper G
Bone Joint J
. 2022 May;
104-B(6):672-679.
PMID: 35638212
Aims: Unicompartmental knee arthroplasty (UKA) has a higher risk of revision than total knee arthroplasty (TKA), particularly for younger patients. The outcome of knee arthroplasty is typically defined as implant...
10.
Vernon-Roberts A, Lopez R, Frampton C, Day A
JPEN J Parenter Enteral Nutr
. 2022 Mar;
46(7):1535-1552.
PMID: 35233792
Background: Parenteral nutrition administered via central venous catheter is an established treatment option for people with intestinal failure. A serious complication of central venous catheters is the high risk of...